Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy
Background - Immune checkpoint blockers have improved survival in metastatic melanoma. Long-term quality of life (QoL) and sequelae from immune-related adverse events (irAE) are therefore of increasing importance. This study reports long-term outcomes from a real-world cohort of patients with stage...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
17 January 2026
|
| In: |
European journal of cancer
Year: 2026, Jahrgang: 233, Pages: 1-12 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2025.116149 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.ejca.2025.116149 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S0959804925010354 
|
| Verfasserangaben: | S. Dugas-Breit, A. Forschner, M. Erdmann, R. Gutzmer, K.C. Kähler, I. Holst, A. Brekner, C. Franklin, A. Sindrilaru, L. Zimmer, L. Heinzerling, J. Utikal, F. Meier, A. Bender, C. Berking, C. Garbe, M. Weichenthal, D. Schadendorf, A. Hauschild, M. Gschnell, P. Mohr, J.C. Hassel |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1961116758 | ||
| 003 | DE-627 | ||
| 005 | 20260217135145.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 260216s2026 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2025.116149 |2 doi | |
| 035 | |a (DE-627)1961116758 | ||
| 035 | |a (DE-599)KXP1961116758 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Dugas-Breit, Susanne |d 1970- |e VerfasserIn |0 (DE-588)121033821 |0 (DE-627)705178153 |0 (DE-576)29250750X |4 aut | |
| 245 | 1 | 0 | |a Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy |c S. Dugas-Breit, A. Forschner, M. Erdmann, R. Gutzmer, K.C. Kähler, I. Holst, A. Brekner, C. Franklin, A. Sindrilaru, L. Zimmer, L. Heinzerling, J. Utikal, F. Meier, A. Bender, C. Berking, C. Garbe, M. Weichenthal, D. Schadendorf, A. Hauschild, M. Gschnell, P. Mohr, J.C. Hassel |
| 264 | 1 | |c 17 January 2026 | |
| 300 | |b Illustrationen | ||
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 29. November 2025, Artikelversion: 11. Dezember 2025 | ||
| 500 | |a Gesehen am 16.02.2026 | ||
| 520 | |a Background - Immune checkpoint blockers have improved survival in metastatic melanoma. Long-term quality of life (QoL) and sequelae from immune-related adverse events (irAE) are therefore of increasing importance. This study reports long-term outcomes from a real-world cohort of patients with stage IV melanoma treated with pembrolizumab after progression on ipilimumab and, if indicated, BRAF/MEK inhibition. - Methods - Survival of patients who started treatment with pembrolizumab within the German Expanded Access Program (EAP) were evaluated in Cancer centers that included ≥10 patients. For survivors, baseline characteristics, best response and irAEs were assessed retrospectively. In addition, in a cross-sectional approach patients were interviewed for persisting symptoms and QoL (WHO-5, EORTC QLQ-C30). - Results - Of 325 treated patients, 55 (17%) survived after a median follow-up of 9.1 years. At treatment start, survivors had a median age of 60 years; 60% were male; 40% BRAF-mutated; 66% stage M1c/d. Overall response rate was 89%, including 69% complete responses. Progression occurred in 22 (40%). As of May 2024, 46 (84%) were disease-free, 7 (13%) had controlled disease, and 2 (4%) progressed. IrAEs occurred in 39 (71%), with 15 (27%) grade 3/4. Persisting symptoms were reported by 19 (35%), mainly endocrine insufficiencies, vitiligo, and fatigue. Median WHO-5 score was 76%, and mean QLQ-C30 global health 70.1. Survivors with prior irAEs had significantly lower QoL (WHO-5, p=0.026) and social functioning (QLQ-C30, p=0.046). Of 21 survivors <65 years (38%), 11 (20%) were employed at follow-up. - Conclusion - Pembrolizumab induced long-term survival in a real-world pretreated melanoma cohort. Despite persisting symptoms in one third, QoL, when measured by standard instruments, was good for most survivors nearly a decade after treatment. | ||
| 650 | 4 | |a Long-term survival | |
| 650 | 4 | |a Long-term toxicity | |
| 650 | 4 | |a Melanoma | |
| 650 | 4 | |a Pembrolizumab | |
| 650 | 4 | |a Quality of life | |
| 700 | 1 | |a Forschner, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Erdmann, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gutzmer, R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kähler, K. C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Holst, I. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brekner, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Franklin, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sindrilaru, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zimmer, L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Heinzerling, L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Utikal, Jochen |d 1974- |e VerfasserIn |0 (DE-588)1026463750 |0 (DE-627)726765015 |0 (DE-576)371816580 |4 aut | |
| 700 | 1 | |a Meier, F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bender, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Berking, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Garbe, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Weichenthal, Michael |e VerfasserIn |0 (DE-588)140953272 |0 (DE-627)623003848 |0 (DE-576)321514157 |4 aut | |
| 700 | 1 | |a Schadendorf, D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hauschild, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gschnell, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mohr, P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hassel, Jessica C. |d 1975- |e VerfasserIn |0 (DE-588)129790702 |0 (DE-627)480399069 |0 (DE-576)29783715X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 233(2026), Artikel-ID 116149, Seite 1-12 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy |
| 773 | 1 | 8 | |g volume:233 |g year:2026 |g elocationid:116149 |g pages:1-12 |g extent:12 |a Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejca.2025.116149 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |7 0 |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0959804925010354 |x Verlag |z kostenfrei |3 Volltext |7 0 |
| 951 | |a AR | ||
| 992 | |a 20260216 | ||
| 993 | |a Article | ||
| 994 | |a 2026 | ||
| 998 | |g 129790702 |a Hassel, Jessica C. |m 129790702:Hassel, Jessica C. |d 910000 |d 911300 |d 50000 |e 910000PH129790702 |e 911300PH129790702 |e 50000PH129790702 |k 0/910000/ |k 1/910000/911300/ |k 0/50000/ |p 22 |y j | ||
| 998 | |g 1026463750 |a Utikal, Jochen |m 1026463750:Utikal, Jochen |d 60000 |e 60000PU1026463750 |k 0/60000/ |p 12 | ||
| 998 | |g 121033821 |a Dugas-Breit, Susanne |m 121033821:Dugas-Breit, Susanne |d 910000 |d 910100 |e 910000PD121033821 |e 910100PD121033821 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1961116758 |e 4918146996 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title_sort":"Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy","title":"Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy"}],"person":[{"family":"Dugas-Breit","role":"aut","display":"Dugas-Breit, Susanne","given":"Susanne"},{"role":"aut","family":"Forschner","given":"A.","display":"Forschner, A."},{"role":"aut","family":"Erdmann","given":"M.","display":"Erdmann, M."},{"display":"Gutzmer, R.","given":"R.","family":"Gutzmer","role":"aut"},{"display":"Kähler, K. C.","given":"K. C.","family":"Kähler","role":"aut"},{"role":"aut","family":"Holst","given":"I.","display":"Holst, I."},{"family":"Brekner","role":"aut","display":"Brekner, A.","given":"A."},{"given":"C.","display":"Franklin, C.","role":"aut","family":"Franklin"},{"given":"A.","display":"Sindrilaru, A.","role":"aut","family":"Sindrilaru"},{"display":"Zimmer, L.","given":"L.","family":"Zimmer","role":"aut"},{"role":"aut","family":"Heinzerling","given":"L.","display":"Heinzerling, L."},{"display":"Utikal, Jochen","given":"Jochen","family":"Utikal","role":"aut"},{"given":"F.","display":"Meier, F.","role":"aut","family":"Meier"},{"role":"aut","family":"Bender","given":"A.","display":"Bender, A."},{"role":"aut","family":"Berking","given":"C.","display":"Berking, C."},{"display":"Garbe, C.","given":"C.","family":"Garbe","role":"aut"},{"given":"Michael","display":"Weichenthal, Michael","role":"aut","family":"Weichenthal"},{"role":"aut","family":"Schadendorf","given":"D.","display":"Schadendorf, D."},{"family":"Hauschild","role":"aut","display":"Hauschild, A.","given":"A."},{"display":"Gschnell, M.","given":"M.","family":"Gschnell","role":"aut"},{"display":"Mohr, P.","given":"P.","family":"Mohr","role":"aut"},{"role":"aut","family":"Hassel","given":"Jessica C.","display":"Hassel, Jessica C."}],"note":["Online verfügbar: 29. November 2025, Artikelversion: 11. Dezember 2025","Gesehen am 16.02.2026"],"id":{"doi":["10.1016/j.ejca.2025.116149"],"eki":["1961116758"]},"name":{"displayForm":["S. Dugas-Breit, A. Forschner, M. Erdmann, R. Gutzmer, K.C. Kähler, I. Holst, A. Brekner, C. Franklin, A. Sindrilaru, L. Zimmer, L. Heinzerling, J. Utikal, F. Meier, A. Bender, C. Berking, C. Garbe, M. Weichenthal, D. Schadendorf, A. Hauschild, M. Gschnell, P. Mohr, J.C. Hassel"]},"physDesc":[{"noteIll":"Illustrationen","extent":"12 S."}],"recId":"1961116758","origin":[{"dateIssuedDisp":"17 January 2026","dateIssuedKey":"2026"}],"relHost":[{"origin":[{"publisher":"Elsevier ; Pergamon Press","dateIssuedKey":"1992","dateIssuedDisp":"1992-","publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]"}],"corporate":[{"role":"isb","display":"European Organization for Research on Treatment of Cancer"},{"role":"isb","display":"European Association for Cancer Research"},{"role":"isb","display":"European School of Oncology"}],"id":{"eki":["266883400"],"zdb":["1468190-0"],"issn":["1879-0852"]},"note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["28.1992 -"],"language":["eng"],"disp":"Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapyEuropean journal of cancer","titleAlt":[{"title":"EJC online"}],"recId":"266883400","title":[{"title":"European journal of cancer","title_sort":"European journal of cancer"}],"part":{"text":"233(2026), Artikel-ID 116149, Seite 1-12","pages":"1-12","extent":"12","year":"2026","volume":"233"}}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"}} | ||
| SRT | |a DUGASBREITCHARACTERI1720 | ||